FDA approves supplement for NUVATION's Ibtrozi (NDA219713)
A new efficacy supplement for the taletrectinib adipate capsule was approved, with the label updated in September 2026.
Drugs@FDA
Latest
5 stories
Monday, September 21
Wednesday, September 16
Thursday, August 6
Nuvation Bio posts Q2 2026 results, expands safusidenib program, reports IBTROZI uptake data
The company reported second-quarter revenue driven by IBTROZI sales, disclosed new long-term safusidenib data, and outlined two new studies for the glioma drug.
SEC filing